These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

876 related articles for article (PubMed ID: 32201353)

  • 21. Blood transfusion during the COVID-19 outbreak.
    Cai X; Ren M; Chen F; Li L; Lei H; Wang X
    Blood Transfus; 2020 Mar; 18(2):79-82. PubMed ID: 32267830
    [No Abstract]   [Full Text] [Related]  

  • 22. Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy.
    Piyush R; Rajarshi K; Khan R; Ray S
    Open Biol; 2020 Sep; 10(9):200174. PubMed ID: 32898468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Convalescent plasma - Is it useful for treating SARS Co-V2 infection?
    Ranganathan S; Iyer RN
    Indian J Med Microbiol; 2020; 38(3 & 4):252-260. PubMed ID: 33154232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Active Therapy with Passive Immunotherapy May Be Effective in the Fight against COVID-19.
    Morabito CJ; Gangadharan B
    Clin Transl Sci; 2020 Sep; 13(5):835-837. PubMed ID: 32420691
    [No Abstract]   [Full Text] [Related]  

  • 25. Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins.
    Xiao K; Zhai J; Feng Y; Zhou N; Zhang X; Zou JJ; Li N; Guo Y; Li X; Shen X; Zhang Z; Shu F; Huang W; Li Y; Zhang Z; Chen RA; Wu YJ; Peng SM; Huang M; Xie WJ; Cai QH; Hou FH; Chen W; Xiao L; Shen Y
    Nature; 2020 Jul; 583(7815):286-289. PubMed ID: 32380510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
    Patil AM; Göthert JR; Khairnar V
    Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19: the epidemiology and treatment.
    Qu L; Li J; Ren H
    Br J Hosp Med (Lond); 2020 Oct; 81(10):1-9. PubMed ID: 33135928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment.
    Yan Y; Shin WI; Pang YX; Meng Y; Lai J; You C; Zhao H; Lester E; Wu T; Pang CH
    Int J Environ Res Public Health; 2020 Mar; 17(7):. PubMed ID: 32235575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidemiological analysis of COVID-19 and practical experience from China.
    Ye Q; Wang B; Mao J; Fu J; Shang S; Shu Q; Zhang T
    J Med Virol; 2020 Jul; 92(7):755-769. PubMed ID: 32237160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 2019 Novel coronavirus: where we are and what we know.
    Cheng ZJ; Shan J
    Infection; 2020 Apr; 48(2):155-163. PubMed ID: 32072569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a review.
    Feng W; Zong W; Wang F; Ju S
    Mol Cancer; 2020 Jun; 19(1):100. PubMed ID: 32487159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COVID-19: Main therapeutic options.
    Hachfi W; Ben Lasfar N
    Tunis Med; 2020 Apr; 98(4):299-303. PubMed ID: 32395792
    [No Abstract]   [Full Text] [Related]  

  • 33. Use of convalescent plasma in COVID-19 patients in China.
    Zhu M; Hu K; Zhu Z
    Transfus Clin Biol; 2020 Aug; 27(3):168-169. PubMed ID: 32425645
    [No Abstract]   [Full Text] [Related]  

  • 34. Virology, transmission, and pathogenesis of SARS-CoV-2.
    Cevik M; Kuppalli K; Kindrachuk J; Peiris M
    BMJ; 2020 Oct; 371():m3862. PubMed ID: 33097561
    [No Abstract]   [Full Text] [Related]  

  • 35. Not just antibodies: B cells and T cells mediate immunity to COVID-19.
    Cox RJ; Brokstad KA
    Nat Rev Immunol; 2020 Oct; 20(10):581-582. PubMed ID: 32839569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2.
    Gupta SP
    Curr Top Med Chem; 2020; 20(26):2362-2378. PubMed ID: 32962613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma.
    Mira E; Yarce OA; Ortega C; Fernández S; Pascual NM; Gómez C; Alvarez MA; Molina IJ; Lama R; Santamaria M
    J Allergy Clin Immunol Pract; 2020 Sep; 8(8):2793-2795. PubMed ID: 32652231
    [No Abstract]   [Full Text] [Related]  

  • 38. Convalescent Plasma: Promise for COVID-19 Pandemic.
    Sheikh S; Baig MA
    J Coll Physicians Surg Pak; 2020 Jun; 30(6):88. PubMed ID: 32723468
    [No Abstract]   [Full Text] [Related]  

  • 39. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SnapShot: COVID-19.
    Oberfeld B; Achanta A; Carpenter K; Chen P; Gilette NM; Langat P; Said JT; Schiff AE; Zhou AS; Barczak AK; Pillai S
    Cell; 2020 May; 181(4):954-954.e1. PubMed ID: 32413300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.